Eli Lilly Just Bet $7.8 Billion on Sleep Disorders
Eli Lilly dropped $7.8 billion on Centessa Pharmaceuticals — a clear signal the pharma giant sees sleep as the next big profit engine beyond GLP-1 weight-loss drugs.
The deal gives Lilly access to orexin agonists, a new class of drugs that target the brain’s sleep-wake cycle. Centessa’s lead candidate, cleminorexton, is in mid-stage trials for narcolepsy and idiopathic hypersomnia. Lilly paid $38 per share — a 37.8% premium — plus a contingent value right worth another $9 per share if milestones hit.
Narcolepsy alone is a $2.5 billion market, but the real opportunity is broader: 50 to 70 million Americans have sleep disorders, and current treatments are limited. If cleminorexton works, Lilly just bought a franchise that could rival its obesity blockbusters in revenue potential — and diversify the portfolio beyond metabolic diseases.
Sleep disorders are chronic, underdiagnosed, and poorly served by existing drugs. That’s exactly the kind of market pharma companies pay a premium to enter. This isn’t speculative biotech gambling — it’s strategic empire-building.
